reports
DGAP-News: Elanix Biotechnologies AG: Korrektur des Jahresabschlusses ...
DGAP-News: Elanix Biotechnologies AG / Schlagwort(e): Sonstiges Elanix Biotechnologies AG: Korrektur des Jahresabschlusses 2015 - Veröffentlichung nach § 109 Absatz 2 Satz 1 WpHG 27.03.2019 / 19:00 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Elanix Biotechnologies AG: Korrektur des Jahresabschlusses 2015 Berlin, 27. März 2019Veröffentlichung nach § 109 Absatz 2 Satz 1 WpHG Die Deutsche Prüfstelle für Rechnungslegung (DPR) hat festgestellt, dass der Konzernabschluss zum Abschlussstichtag 31.12.2015 der Elanix Biotechnologies AG, Berlin, fehlerhaft...
DGAP-News: Elanix Biotechnologies AG: Correction of 2015 Financial Sta...
DGAP-News: Elanix Biotechnologies AG / Key word(s): Miscellaneous Elanix Biotechnologies AG: Correction of 2015 Financial Statements - Release according to § 109 Paragraph 2 Sentence 1 WpHG 27.03.2019 / 19:00 The issuer is solely responsible for the content of this announcement. Elanix Biotechnologies AG: Correction of 2015 Financial Statements Berlin, March 27, 2019 Release according to § 109 Paragraph 2 Sentence 1 WpHG  The German Financial Reporting Enforcement Panel (FREP) determined that the consolidated financial statements of Elanix Biotechnologies AG, Berlin, for the year...
DGAP-News: Elanix Biotechnologies AG: Frau Prof. Lee Ann Laurent-Apple...
DGAP-News: Elanix Biotechnologies AG / Schlagwort(e): Personalie Elanix Biotechnologies AG: Frau Prof. Lee Ann Laurent-Applegate wird neuer Vorstand 12.11.2018 / 16:49 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Frau Prof. Lee Ann Laurent-Applegate wird neuer Elanix Biotechnologies AG Vorstand Berlin, 12.11.2018 - Der Aufsichtsrat der Elanix Biotechnologies AG hat die Gründerin und Hauptaktionärin Frau Lee Ann Laurent-Applegate zum Vorstand und Interim-CEO bestellt. Frau Prof. Lee Ann Laurent-Applegate und der Aufsichtsrat freuen sich darauf, die Elani...
DGAP-News: Elanix Biotechnologies AG: Elanix Biotechnologies AG has pl...
DGAP-News: Elanix Biotechnologies AG / Key word(s): Capital Increase/Financing Elanix Biotechnologies AG: Elanix Biotechnologies AG has placed 301,763 shares of the current cash capital increase and is negotiating further financing opportunities 01.10.2018 / 11:08 The issuer is solely responsible for the content of this announcement. THE INFORMATION CONTAINED IN THIS RELEASE IS NOT TO BE PUBLISHED OR FORWARDEDÂ IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER COUNTRY WHERE SUCH A DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL Â Â Berlin, 1 October 2018 - ...
DGAP-News: Elanix Biotechnologies AG: Elanix Biotechnologies AG platzi...
DGAP-News: Elanix Biotechnologies AG / Schlagwort(e): Kapitalerhöhung/Finanzierung Elanix Biotechnologies AG: Elanix Biotechnologies AG platziert 301.763 Aktien in der laufenden Kapitalerhöhung und verhandelt weitere Finanzierungsoptionen 01.10.2018 / 11:08 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. DIE IN DIESER MITTEILUNG ENTHALTENEN INFORMATIONEN SIND WEDER ZURVERÖFFENTLICHUNG NOCH ZUR WEITERGABE IN BZW. INNERHALB DER VEREINIGTENSTAATEN VON AMERIKA, AUSTRALIEN, KANADA ODER JAPAN ODER IN SONSTIGE LÄNDER, IN DENEN EINE SOLCHE VERBREITUNG ODER VERÖ...
Elanix Biotechnologies AG Raises EUR 1.125 Million Gross Proceeds from...
BERLIN--(BUSINESS WIRE)-- The information in this announcement is NOT for publication OR distribution in or into the United States of America, Australia, Canada or any jurisdiction in which such distribution or publication could be unlawful Elanix Biotechnologies AG ("Elanix"; "the company"), a developer of tissue regeneration products and specialty cosmetics in the field of dermatology and gynecology, announced today the completion of a capital increase approved by the General Shareholder Assembly (“GSM”) on 24 ...
A director bought 10,000 shares at 5.390EUR and
A director at ELANIX BIOTECHNOLOGIES AG bought 10,000 shares at 5.390EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Elanix Biotechnologies lance une application mobile pour la crème de ...
NYON, Suisse & POTSDAM, Allemagne--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FRA: ELN), développeur de produits de régénération tissulaire et de cosmétiques spécialisés dans la dermatologie et la gynécologie, a annoncé aujourd'hui le lancement d'une application mobile pour la créme GYNrepair®. Spécialement conçue pour être appliquée sur la muqueuse intime externe, la crème GYNrepair® apaise la sensation d'inconfort, de tiraillements et de la sécheresse. GYNrepair® contient le Cell Free Protein Complex (CFPC®) propriétaire, r...
Elanix Biotechnologies Launches Adherence App for GYNrepair® Women’...
NYON, Switzerland & POTSDAM, Germany--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, announced today the launch of an adherence app for its topical women’s health product, GYNrepair® cream. Specifically designed for use on the intimate external mucosa, GYNrepair® cream soothes the feeling of discomfort, twinges and dryness. GYNrepair® cream contains a proprietary Cell Free Protein Complex (CFPC®), including various protei...
Elanix Biotechnologies lance la commercialisation en Europe de la crè...
NYON, Suisse & POTSDAM, Allemagne--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FRA: ELN), développe des produits de régénération de tissus et de cosmétiques spécialisés en dermatologie et gynécologie, Elanix Biotechnologies annonce aujourd'hui le lancement de son produit pour le confort de la zone intime externe chez la femme, GYNrepair® Cream dans l'Union européenne. La crème GYNrepair® contient un complexe de protéines de cellules (CFPC®), composé de protéines, comme le collagène et la fibronectine, celui ne contient pas de ...
Elanix Biotechnologies Starts EU Commercialization of GYNrepair® Crea...
NYON, Switzerland & POTSDAM, Germany--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, announced today the launch of its topical women’s health product, GYNrepair® Cream in the European Union. GYNrepair® Cream contains a proprietary Cell Free Protein Complex (CFPC®), including various proteins, such as collagen and fibronectin, and is perfume-free. It is specifically designed for use on the genital external mucosa to soothe...
Elanix Signs Agreement with Apraxon to Establish European Logistics Ce...
NYON, Switzerland & POTSDAM, Germany--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FSE: ELN.F), a developer of tissue regeneration products, announced today the signing of an agreement with Apraxon GmbH to establish a logistics center in Hofbieber, near Frankfurt, Germany. In anticipation of expanded commercialization activities for Elanix’s topical women’s health cream, GYNrepair®, the European logistics center will initially coordinate all storage and shipping of the product. Of significant importance will also be Apraxon’s ability ...
Elanix Acquires Third Cell Based Bioactive Cream Formulation with Pote...
NYON, Switzerland & POTSDAM, Germany--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FSE: ELN), a developer of tissue regeneration products, announced today that its wholly owned subsidiary, Repair-A Ltd, has acquired a third cell free protein complex (CFPC®) product discovered in the Tec-Pharm laboratories of Professor Lee-Ann Laurent Applegate. Financial terms were not disclosed. This new cream could potentially be used to alleviate a significant dermatological condition and particularly for pediatric use, which affects over 10% of th...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Elanix Biotechnologies AG Strategic Partner, Transwell Biotechnology L...
NYON, Switzerland & POTSDAM, Germany--(BUSINESS WIRE)-- Elanix Biotechnologies AG (“Elanix” - FSE: ELN), a developer of tissue regeneration and cosmetic products, announces that their licensed partner Transwell Biotechnology Ltd. (subsidiary of Easywell Biomedicals Ltd., Hsinchu, Taiwan) has received investigational new drug (IND) clearance from the US FDA to conduct combined Phase I/II clinical trial. The trial is titled "A phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft ...
Elanix signe des accords d’approvisionnement et de fabrication avec ...
NYON, Suisse & POTSDAM, Allemagne--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FSE:ELN), un développeur de produits de régénération tissulaire, a annoncé aujourd'hui la signature d'accords d'approvisionnement avec deux sociétés suisses, Sincopharm SA et Tec-Pharma SA. Les accords assureront une durabilité de fabrication de haute qualité et une fiabilité d’approvisionnement pour deux produits cosmétiques bioactive disponibles dans le commerce. Produit soulageant les conditions gynécologiques et dermatologiques, obtenu à partir de l'ac...
Elanix Signs Supply and Manufacturing Agreements with Sincopharm and T...
NYON, Switzerland & POTSDAM, Germany--(BUSINESS WIRE)-- Elanix Biotechnologies AG (FSE:ELN), a developer of tissue regeneration products, announced today the signing of supply agreements with two Swiss companies, Sincopharm SA and Tec-Pharma SA. The agreements will assure manufacturing sustainability at high quality and supply reliability of two commercially available medical cosmetic products, to alleviate gynecological and dermatological conditions, obtained from the recent acquisition of Repair-A SA. Elanix now has complet...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.